Eosinophil activation by prostaglandin D-2 and its modulation by seratrodast

Citation
S. Takafuji et al., Eosinophil activation by prostaglandin D-2 and its modulation by seratrodast, INT A AL IM, 124(1-3), 2001, pp. 365-366
Citations number
3
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Immunology
Journal title
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
ISSN journal
1018-2438 → ACNP
Volume
124
Issue
1-3
Year of publication
2001
Pages
365 - 366
Database
ISI
SICI code
1018-2438(200101/03)124:1-3<365:EABPDA>2.0.ZU;2-F
Abstract
Background: Seratrodast is one of the antiallergic drugs and causes antagon ism not only to thromboxane A(2) but also to prostaglandin D-2 (PGD(2)). It has been reported that PGD(2) increases cytosolic free calcium concentrati on ([Ca2+](i)) in human eosinophils. In this study, we have examined the ef fect of seratrodast on eosinophil cationic protein (ECP) release and change s of [Ca2+](i) in human eosinophils induced by PGD(2). Methods: Eosinophils from healthy donors were incubated with or without IL-3 for 10 min after i ncubation with or without seratrodast for 15 min, Then, they were stimulate d with PGD(2) for 20 min after incubation with cytochalasin B for 10 min, R esults: PGD(2) induced significant ECP release in IL-3-primed eosinophils, This ECP release was significantly inhibited by seratrodast. Seratrodast ha d no effect on ECP release induced by PAF in IL-3-primed eosinophils. Furth ermore, pretreatment with seratrodast inhibited cytosolic calcium increase induced by PGD(2) in human eosinophils, and it had no effect on that induce d by PAF. Conclusions: This study shows that PGD(2) induces ECP release in IL-3-primed eosinophils and that seratrodast suppresses its effect. This in hibition by seratrodast may contribute to its clinical efficacy in the trea tment of bronchial asthma, Copyright (C) 2001 S. Karger AG, Basel.